Literature DB >> 28031179

PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR.

Elise A Chong1, J Joseph Melenhorst2, Simon F Lacey2, David E Ambrose2, Vanessa Gonzalez2, Bruce L Levine2, Carl H June2, Stephen J Schuster1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 28031179      PMCID： PMC5391777          DOI： 10.1182/blood-2016-09-738245

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  8 in total

1.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

2.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.

Authors:  Julie R Brahmer; Scott S Tykodi; Laura Q M Chow; Wen-Jen Hwu; Suzanne L Topalian; Patrick Hwu; Charles G Drake; Luis H Camacho; John Kauh; Kunle Odunsi; Henry C Pitot; Omid Hamid; Shailender Bhatia; Renato Martins; Keith Eaton; Shuming Chen; Theresa M Salay; Suresh Alaparthy; Joseph F Grosso; Alan J Korman; Susan M Parker; Shruti Agrawal; Stacie M Goldberg; Drew M Pardoll; Ashok Gupta; Jon M Wigginton
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

3.  Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo.

Authors:  Michael C Milone; Jonathan D Fish; Carmine Carpenito; Richard G Carroll; Gwendolyn K Binder; David Teachey; Minu Samanta; Mehdi Lakhal; Brian Gloss; Gwenn Danet-Desnoyers; Dario Campana; James L Riley; Stephan A Grupp; Carl H June
Journal:  Mol Ther       Date:  2009-04-21       Impact factor: 11.454

4.  Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia.

Authors:  David L Porter; Wei-Ting Hwang; Noelle V Frey; Simon F Lacey; Pamela A Shaw; Alison W Loren; Adam Bagg; Katherine T Marcucci; Angela Shen; Vanessa Gonzalez; David Ambrose; Stephan A Grupp; Anne Chew; Zhaohui Zheng; Michael C Milone; Bruce L Levine; Jan J Melenhorst; Carl H June
Journal:  Sci Transl Med       Date:  2015-09-02       Impact factor: 17.956

5.  Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells.

Authors:  Liza B John; Christel Devaud; Connie P M Duong; Carmen S Yong; Paul A Beavis; Nicole M Haynes; Melvyn T Chow; Mark J Smyth; Michael H Kershaw; Phillip K Darcy
Journal:  Clin Cancer Res       Date:  2013-07-19       Impact factor: 12.531

6.  Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.

Authors:  Suzanne L Topalian; Mario Sznol; David F McDermott; Harriet M Kluger; Richard D Carvajal; William H Sharfman; Julie R Brahmer; Donald P Lawrence; Michael B Atkins; John D Powderly; Philip D Leming; Evan J Lipson; Igor Puzanov; David C Smith; Janis M Taube; Jon M Wigginton; Georgia D Kollia; Ashok Gupta; Drew M Pardoll; Jeffrey A Sosman; F Stephen Hodi
Journal:  J Clin Oncol       Date:  2014-03-03       Impact factor: 44.544

7.  Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.

Authors:  Omid Hamid; Caroline Robert; Adil Daud; F Stephen Hodi; Wen-Jen Hwu; Richard Kefford; Jedd D Wolchok; Peter Hersey; Richard W Joseph; Jeffrey S Weber; Roxana Dronca; Tara C Gangadhar; Amita Patnaik; Hassane Zarour; Anthony M Joshua; Kevin Gergich; Jeroen Elassaiss-Schaap; Alain Algazi; Christine Mateus; Peter Boasberg; Paul C Tumeh; Bartosz Chmielowski; Scot W Ebbinghaus; Xiaoyun Nicole Li; S Peter Kang; Antoni Ribas
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245

8.  Nivolumab plus ipilimumab in advanced melanoma.

Authors:  Jedd D Wolchok; Harriet Kluger; Margaret K Callahan; Michael A Postow; Naiyer A Rizvi; Alexander M Lesokhin; Neil H Segal; Charlotte E Ariyan; Ruth-Ann Gordon; Kathleen Reed; Matthew M Burke; Anne Caldwell; Stephanie A Kronenberg; Blessing U Agunwamba; Xiaoling Zhang; Israel Lowy; Hector David Inzunza; William Feely; Christine E Horak; Quan Hong; Alan J Korman; Jon M Wigginton; Ashok Gupta; Mario Sznol
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245
  8 in total
  181 in total

1.  Phase I clinical trial of EGFR-specific CAR-T cells generated by the piggyBac transposon system in advanced relapsed/refractory non-small cell lung cancer patients.

Authors:  Yajun Zhang; Zhiwei Zhang; Yongmei Ding; Yuan Fang; Pei Wang; Wenqi Chu; Zhenlin Jin; Xintao Yang; Jiangtao Wang; Jinxing Lou; Qijun Qian
Journal:  J Cancer Res Clin Oncol       Date:  2021-05-25       Impact factor: 4.553

Review 2.  Recent advances and discoveries in the mechanisms and functions of CAR T cells.

Authors:  Rebecca C Larson; Marcela V Maus
Journal:  Nat Rev Cancer       Date:  2021-01-22       Impact factor: 60.716

Review 3.  Recent advances in tumor associated carbohydrate antigen based chimeric antigen receptor T cells and bispecific antibodies for anti-cancer immunotherapy.

Authors:  Zahra Rashidijahanabad; Xuefei Huang
Journal:  Semin Immunol       Date:  2020-01-22       Impact factor: 11.130

Review 4.  Personal tumor antigens in blood malignancies: genomics-directed identification and targeting.

Authors:  Livius Penter; Catherine J Wu
Journal:  J Clin Invest       Date:  2020-04-01       Impact factor: 14.808

Review 5.  An Update on the Use of Immunotherapy in the Treatment of Lymphoma.

Authors:  Thomas U Marron; Matko Kalac; Joshua Brody
Journal:  Curr Hematol Malig Rep       Date:  2017-08       Impact factor: 3.952

Review 6.  A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma.

Authors:  Houli Zhao; Yiyun Wang; Elaine Tan Su Yin; Kui Zhao; Yongxian Hu; He Huang
Journal:  Front Med       Date:  2020-12-01       Impact factor: 4.592

7.  BiTEs better than CAR T cells.

Authors:  Marion Subklewe
Journal:  Blood Adv       Date:  2021-01-26

8.  A Novel Target Antigen for the Treatment of Acute Myeloid Leukemia by CAR T Cells.

Authors:  Paul A Beavis; Kevin Sek; Phillip K Darcy
Journal:  Mol Ther       Date:  2017-07-14       Impact factor: 11.454

9.  IL-15 Preconditioning Augments CAR T Cell Responses to Checkpoint Blockade for Improved Treatment of Solid Tumors.

Authors:  Lauren Giuffrida; Kevin Sek; Melissa A Henderson; Imran G House; Junyun Lai; Amanda X Y Chen; Kirsten L Todd; Emma V Petley; Sherly Mardiana; Izabela Todorovski; Emily Gruber; Madison J Kelly; Benjamin J Solomon; Stephin J Vervoort; Ricky W Johnstone; Ian A Parish; Paul J Neeson; Lev M Kats; Phillip K Darcy; Paul A Beavis
Journal:  Mol Ther       Date:  2020-07-21       Impact factor: 11.454

Review 10.  Current development of chimeric antigen receptor T-cell therapy.

Authors:  Jiasheng Wang; Yongxian Hu; He Huang
Journal:  Stem Cell Investig       Date:  2018-12-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.